616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Triplet Combinations of Novel Therapies
Patrick K Reville, Hagop Kantarjian, Gautam Borthakur, et al.
CLAD / LDAC + VEN alternating with AZA + VEN is an effective, lower-intensity therapy. It is well tolerated by patients newly diagnosed with AML (≥ 60 years of age). High response rates with encouraging OS and DFS as well as permanent MRD-negative remissions were observed, with comparable efficacy ≥ 70 and <70 years.
Chong Chyn Chua, John Reynolds, Anoop Kumar Enjeti, et al.
MIDO or PRAN plus VEN-LDAC is tolerated by elderly/unfit patients with treatment-naive AML. This risk-stratified approach was accompanied by a Preliminary favorable efficacy compared to previous studies with VEN-LDAC.
Gail J. Roboz, Thomas Pabst, Ahmed Aribi, et al.
Cusatuzumab plus venetoclax and azacitidine in elderly patients with untreated AML were generally well tolerated. The safety profile was similar to that of VEN-AZA, in addition to generally manageable IRRs. The response rates suggest an additive effect of cusatuzumab to the standard treatment. According to the study authors, this therapy has the potential for improved clinical outcomes.
Musa Yilmaz, Muharrem Muftuoglu, Hagop Kantarjian, et al.
According to the study authors, the combination of DAC + VEN + Quiz is active in heavily pretreated and previously FLT3i-exposed (including 68% with previous gilteritinib) R / R FLT3-ITDm patients. The CRc rate was 65 percent and a median overall survival of 7.5 months. The overall survival after one year was 34 percent. Quiz 30mg QDay was established as the RP2D for the triplet. In this triplet, too, RAS / MAPK mutations are associated with primary and secondary resistance. Updated clinical, NGS, and mass cytometry data will be presented in the oral session.
Naval Daver, Marina Konopleva, Abhishek Maiti, et al.
Azacitidine (AZA) with Venetoclax (VEN) plus Magrolimab (Magro) in ND patients is a safe combination therapy and leads to high CR / CRi rates (94%) and CR rates (81%). The majority (82%) were affected by the ELN adverse risk. ANC and platelet recovery were robust. Early-onset anemia should be monitored.
Naval Daver, Ahmed Aribi, Pau Montesinos, et al.
This novel IMGN632 triplet had convincing anti-leukemia activity in R / R-AML patients. The security profile is manageable. Updated data on safety, efficacy, and PK will be presented in the oral session.